[go: up one dir, main page]

JPS6461429A - Remedy for cancer - Google Patents

Remedy for cancer

Info

Publication number
JPS6461429A
JPS6461429A JP21616887A JP21616887A JPS6461429A JP S6461429 A JPS6461429 A JP S6461429A JP 21616887 A JP21616887 A JP 21616887A JP 21616887 A JP21616887 A JP 21616887A JP S6461429 A JPS6461429 A JP S6461429A
Authority
JP
Japan
Prior art keywords
chitosan
remedy
lymph nodes
anticancer agent
cancer
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP21616887A
Other languages
Japanese (ja)
Inventor
Akio Hagiwara
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Individual
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Individual filed Critical Individual
Priority to JP21616887A priority Critical patent/JPS6461429A/en
Publication of JPS6461429A publication Critical patent/JPS6461429A/en
Pending legal-status Critical Current

Links

Landscapes

  • Medicinal Preparation (AREA)

Abstract

PURPOSE:To obtain a remedy for cancer, having directional properties to lymph nodes, etc., and capable of selectively concentrating and staying on affected parts and keeping activity for a long period, by blending a specific amount of chitosan with an anticancer agent. CONSTITUTION:A remedy for cancer obtained by blending chitosan having 10,000-1,000,000mol.wt. with an anticancer agent (e.g. bleomycin). The chitosan as an adsorbent is converted into a state adsorbed on the anticancer agent. When the chitosan is administered into the body by a method for injection, etc., a prepared pharmaceutical thereof has also directional properties to lymph nodes, etc., since the chitosan has excellent directional properties to the lymph nodes, etc. If the chitosan is administered to tissue, it selectively concentrates on affected parts and stays to keep the activity for a long period. The chitosan is metabolized in vivo and discharged.
JP21616887A 1987-08-29 1987-08-29 Remedy for cancer Pending JPS6461429A (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
JP21616887A JPS6461429A (en) 1987-08-29 1987-08-29 Remedy for cancer

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
JP21616887A JPS6461429A (en) 1987-08-29 1987-08-29 Remedy for cancer

Publications (1)

Publication Number Publication Date
JPS6461429A true JPS6461429A (en) 1989-03-08

Family

ID=16684352

Family Applications (1)

Application Number Title Priority Date Filing Date
JP21616887A Pending JPS6461429A (en) 1987-08-29 1987-08-29 Remedy for cancer

Country Status (1)

Country Link
JP (1) JPS6461429A (en)

Cited By (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5204107A (en) * 1990-11-20 1993-04-20 Unitika Ltd. Slow-releasing composition of platinum-containing anticancer agent
WO1995008991A1 (en) * 1993-09-30 1995-04-06 Board Of Regents, The University Of Texas System Parenteral busulfan for treatment of malignant disease
KR20010035311A (en) * 2001-02-02 2001-05-07 윤재화 A COMPOSITION FOR AN ANTI-CANCER EFFECTS CONTAINING CHITOSAN, β- GLUCAN OF AGARCUS MUSH-ROOMS AND ORGANIC GERMANIUM
WO2003015827A1 (en) * 2001-08-18 2003-02-27 Korea Institute Of Science And Technology Anticancer drug-chitosan complex forming self-aggregates and preparation method thereof

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS6440418A (en) * 1987-08-07 1989-02-10 Arusu Japan Kk Sustained release material for drug

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS6440418A (en) * 1987-08-07 1989-02-10 Arusu Japan Kk Sustained release material for drug

Cited By (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5204107A (en) * 1990-11-20 1993-04-20 Unitika Ltd. Slow-releasing composition of platinum-containing anticancer agent
WO1995008991A1 (en) * 1993-09-30 1995-04-06 Board Of Regents, The University Of Texas System Parenteral busulfan for treatment of malignant disease
KR20010035311A (en) * 2001-02-02 2001-05-07 윤재화 A COMPOSITION FOR AN ANTI-CANCER EFFECTS CONTAINING CHITOSAN, β- GLUCAN OF AGARCUS MUSH-ROOMS AND ORGANIC GERMANIUM
WO2003015827A1 (en) * 2001-08-18 2003-02-27 Korea Institute Of Science And Technology Anticancer drug-chitosan complex forming self-aggregates and preparation method thereof
US7511023B2 (en) 2001-08-18 2009-03-31 Korea Institute Of Science And Technology Anticancer drug-chitosan complex forming self-aggregates and preparation method thereof

Similar Documents

Publication Publication Date Title
HK28097A (en) Cyclosporin-containing pharmaceutical composition
EP0330201A3 (en) Method of enhancing the effect of cytotoxic agents
TW250435B (en)
ATE76747T1 (en) PHARMACEUTICAL COMPOSITIONS CONTAINING LEVODOPA METHYL ESTER, THEIR PREPARATION AND THERAPEUTIC USES.
AU3074289A (en) 2,2'-iminobisethanol derivatives as potentiators of the effects of blood pressure reducing agents
IL99290A0 (en) Nonaqueous fluorinated drug delivery vehicle suspensions
MX9603925A (en) Combinations of thrombolytically active proteins and anticoagulants, and uses thereof.
CA2382013A1 (en) Pharmaceutical solutions of levosimendan
PT615754E (en) SOLID FORMS OF CONTROLLED LIBERATION ORAL ADMINISTRATION FLUPERTINE
GEP20043162B (en) Derivatives of Isosorbid Mononitrate, Utilization as Vasodilator Agents with Reduced Tolerance
CA2280773A1 (en) Methods for the administration of amifostine
JPS6434909A (en) Cosmetic
JPS6461429A (en) Remedy for cancer
AU3024389A (en) Therapeutic agent for the prevention of intraventricular hemorrhage in premature infants
EP1023901A4 (en) Ameliorant for hepatitis c remedial effect and application thereof
EP1621207A3 (en) Mixture of defibrotide and G-CSF, and its use for activating haematopoietic progenitors
EP0147185A3 (en) Therapeutic use of cytidyl disphosphocholine to increase neuronal acetylcholine
AU570552B2 (en) 1,4-dihydropyridine-3-carboxylates and salts thereof
EP0257887A3 (en) Ophthalmic compositions
RU96118929A (en) METHOD FOR INCREASING PROTECTIVE PROPERTIES OF THE BODY UNDER THE INFLUENCE OF EXTERNAL PHYSICAL FACTORS
CA2091134A1 (en) Therapeutic agent for threatened abortion
TWI263502B (en) Pharmaceutical preparation for treating ischemic disease of heart or limbs
EP0193164A3 (en) Sustained-release pharmaceutical preparation which comprised 2-nitroxy-methyl-6-chloropyridine, process for its preparation and use thereof
FR2572932B1 (en) INSOLUBLE DRUG LOCALLY ADMINISTERED IN THE EAR
IE44461L (en) Piperazinyluracil salts